Spots Global Cancer Trial Database for induction
Every month we try and update this database with for induction cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) | NCT00910897 | Multiple Myelom... | Velcade-Dexamet... Velcade-Thalido... | 18 Years - 65 Years | Intergroupe Francophone du Myelome | |
| Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma | NCT05489887 | High-risk Neuro... | Naxitamab Ceritinib | 12 Months - 21 Years | Milton S. Hershey Medical Center | |
| Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | NCT04208178 | Advanced HER2+B... | Alpelisib Alpelisib match... Trastuzumab Pertuzumab | 18 Years - | Novartis | |
| Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma | NCT00722930 | Follicular Lymp... | Y90 Ibritumomab... | 18 Years - | Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas | |
| Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance | NCT06070961 | Follicular Lymp... | Cellular immuni... Humoral immunit... Cellular immuni... Humoral immunit... Diphtheria toxi... Tetanus toxoid-... T-cell populati... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT01412229 | Head and Neck C... | Cetuximab Nab-paclitaxel Carboplatin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim | NCT00280787 | Non Small Cell ... | Paclitaxel Carboplatin CPT-11 Pegfilgrastim Conformal radio... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy | NCT02624570 | Acute Myeloid L... FLT3 Mutation, ... | Midostaurin | 18 Years - | Novartis | |
| Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma | NCT00442637 | Colorectal Canc... | capecitabine + ... observation | 18 Years - | Dutch Colorectal Cancer Group | |
| Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim | NCT00280787 | Non Small Cell ... | Paclitaxel Carboplatin CPT-11 Pegfilgrastim Conformal radio... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) | NCT00910897 | Multiple Myelom... | Velcade-Dexamet... Velcade-Thalido... | 18 Years - 65 Years | Intergroupe Francophone du Myelome | |
| Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia | NCT02440178 | Acute Leukemia | Micafungin | 18 Years - 75 Years | Seoul National University Hospital | |
| Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML | NCT02306291 | Leukemia, Myelo... | GMI-1271 Mitoxantrone Etoposide Cytarabine Idarubicin | 18 Years - | GlycoMimetics Incorporated | |
| Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT01412229 | Head and Neck C... | Cetuximab Nab-paclitaxel Carboplatin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma | NCT05489887 | High-risk Neuro... | Naxitamab Ceritinib | 12 Months - 21 Years | Milton S. Hershey Medical Center | |
| Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease | NCT00552058 | Crohn Disease | certolizumab pe... Placebo | 18 Years - 75 Years | UCB Pharma | |
| Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease | NCT00552058 | Crohn Disease | certolizumab pe... Placebo | 18 Years - 75 Years | UCB Pharma | |
| IA14 Induction in Young Acute Myeloid Leukemia | NCT04069208 | Acute Myeloid L... | Idarubicin and ... | 18 Years - 60 Years | Peking Union Medical College Hospital | |
| Personalized Therapy of Precursor Lymphoid Neoplasms | NCT01665001 | Precursor Lymph... | Treatment strat... | 18 Years - | Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice | |
| Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT01412229 | Head and Neck C... | Cetuximab Nab-paclitaxel Carboplatin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma | NCT00442637 | Colorectal Canc... | capecitabine + ... observation | 18 Years - | Dutch Colorectal Cancer Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
